This prospective, single-center observational study aims to compare the clinical performance, workflow efficiency, and electrophysiological metrics of two commercially available, high-density multielectrode mapping catheters (Octaray and Optrell) in patients undergoing catheter ablation for complex atrial arrhythmias. The primary focus is to determine if the real-time vector propagation capabilities of the Optrell catheter combined with V8 software can accurately confirm conduction block across linear ablation lesions without the need for full-chamber activation remapping, which is the current standard of care. A secondary focus will pair-compare the bipolar voltage amplitude distributions recorded by both catheters, given their differing electrode sizes and spacing.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
30
Comparison between two mapping catheters, Optrell vs Octaray, in the same patient
Shamir Medical Center
Be’er Ya‘aqov, Israel
RECRUITINGConcordance
Percentage of agreement (presence vs. absence of bidirectional block) between the Optrell real-time vector assessment and standard activation remapping on a per-line basis.
Time frame: During ablation procedure
Workflow Efficiency
Difference in time (in minutes) required to confirm conduction block status using the Optrell vector method versus full activation mapping.
Time frame: During ablation procedure
Bipolar Voltage Correlation
Statistical correlation and evaluation of systematic bias (limits of agreement) between the bipolar voltage amplitudes recorded by the two catheters in matched anatomical regions.
Time frame: During ablation procedure
Multipolar Voltage Correlation
Statistical correlation and evaluation of systematic bias (limits of agreement) between the multipolar voltage amplitudes recorded by the Optrell catheter and the bipolar voltage amplitudes recorded by the Octaray catheter in matched anatomical regions.
Time frame: During ablation procedure
Clinical Efficacy
Freedom from any documented atrial tachyarrhythmia lasting ≥30 seconds at 1, 3, 6, 9, and 12 months
Time frame: 12 month follow up period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.